

Sanford Health South Region Antibiogram

Gram Negative Organisms

2025 Antibiogram (Jan-Dec 2024 data)	<i>Acinetobacter baumannii</i> complex	<i>Citrobacter freundii</i> complex	<i>Enterobacter cloacae</i> complex	<i>Enterobacter cloacae</i> complex, CRE	<i>Escherichia coli</i>	<i>Escherichia coli</i> , ESBL	<i>Klebsiella (Enterobacter) aerogenes</i>	<i>Klebsiella oxytoca</i>	<i>Klebsiella pneumoniae</i>	<i>Klebsiella pneumoniae</i> , ESBL	<i>Proteus mirabilis</i>	<i>Proteus mirabilis</i> , ESBL	<i>Salmonella</i> species ^a	<i>Serratia marcescens</i>	<i>Pseudomonas aeruginosa</i>	<i>Pseudomonas aeruginosa</i> , CRPA	<i>Stenotrophomonas maltophilia</i>	<i>Haemophilus influenzae</i> ^a	
	Isolates (N)	32	509	550	45	11403	531	318	417	1905	89	811	32	42	159	998	53	87	35
Antibiotic	Susceptible (%)																		
Ampicillin	R	R	R	R	62	*	R	R	R	R	83	*	88	R	R	R	R	R	69
Ampicillin/ Sulbactam	100	R	R	R	71	*	R	74	87	*	87	*	-	R	R	R	R	R	-
Piperacillin/ Tazobactam	68	86	74	4	96	*	76	93	93	*	100	*	-	94 ^b	91	60	R	R	-
Cefazolin ^c	R	R	R	R	93	*	R	-	95	*	94	*	R	R	R	R	R	R	-
Ceftazidime	75	-	-	-	-	-	-	-	-	-	-	-	-	-	94	69	-	-	-
Ceftriaxone	-	-	-	-	94	*	78	94	95	*	96	*	90	96	R	R	R	R	100
Cefepime	-	98	94	66	96	*	99	99	96	*	97	*	-	99	93	64	-	-	-
Aztreonam	R	-	-	-	-	-	-	-	-	-	-	-	-	-	83	45	R	R	-
Ertapenem	R	99	91	0	100	100	96	100	100	100	100	100	-	98	R	R	R	R	-
Meropenem	-	-	-	-	-	-	-	-	-	-	-	-	100 ^b	-	95	0	R	R	100 ^b
Ciprofloxacin	90	96	96	84	85	26	97	99	93	20	80	18	83	93	87	58	-	-	-
Levofloxacin	96	95	94	77	81	16	94	98	91	12	80	25	-	94	82	45	91	R	-
Gentamicin	96	99	99	100	93	76	100	100	97	56	90	37	R	99	R	R	R	R	-
Tobramycin	100	99	99	95	93	69	100	99	97	53	91	18	R	86	98	88	R	R	-
Trimethoprim/ Sulfamethoxazole	93	96	94	91	81	47	99	97	94	24	85	12	92	99	R	R	R	88	-
Nitrofurantoin ^c	-	88	42	51	98	90	13	85	28	13	R	R	-	R	R	R	R	-	-

a) Results from 2023 and 2024; invasive isolates only

b) < 30 isolates or subset of total isolates; results may not be statistically significant

c) urine only

-) not tested, not reported, or insufficient data

*) reported as resistant for ESBL; treatment not recommended

R) intrinsically resistant or clinically ineffective; treatment not recommended

% susceptible ≥ 90

% susceptible 60-89

% susceptible < 60 or R

Traffic light color palette

Sanford Health South Region Antibigram

Gram Negative Organisms

2025 Antibigram (Jan-Dec 2024 data)	<i>Acinetobacter baumannii</i> complex	<i>Citrobacter freundii</i> complex	<i>Enterobacter cloacae</i> complex	<i>Enterobacter cloacae</i> complex, CRE	<i>Escherichia coli</i>	<i>Escherichia coli</i> , ESBL	<i>Klebsiella (Enterobacter) aerogenes</i>	<i>Klebsiella oxytoca</i>	<i>Klebsiella pneumoniae</i>	<i>Klebsiella pneumoniae</i> , ESBL	<i>Proteus mirabilis</i>	<i>Proteus mirabilis</i> , ESBL	<i>Salmonella</i> species ^a	<i>Serratia marcescens</i>	<i>Pseudomonas aeruginosa</i>	<i>Pseudomonas aeruginosa</i> , CRPA	<i>Stenotrophomonas maltophilia</i>	<i>Haemophilus influenzae</i> ^a	
	Isolates (N)	32	509	550	45	11403	531	318	417	1905	89	811	32	42	159	998	53	87	35
Antibiotic	Susceptible (%)																		
Ampicillin	R	R	R	R	62	*	R	R	R	*	83	*	88	R	R	R	R	R	69
Ampicillin/ Sulbactam	100	R	R	R	71	*	R	74	87	*	87	*	-	R	R	R	R	R	-
Piperacillin/ Tazobactam	68	86	74	4	96	*	76	93	93	*	100	*	-	94 ^b	91	60	R	-	
Cefazolin ^c	R	R	R	R	93	*	R	-	95	*	94	*	R	R	R	R	R	R	-
Ceftazidime	75	-	-	-	-	-	-	-	-	-	-	-	-	-	94	69	-	-	
Ceftriaxone	-	-	-	-	94	*	78	94	95	*	96	*	90	96	-	-	R	100	
Cefepime	-	98	94	66	96	*	99	99	96	*	97	*	-	99	93	64	-	-	
Aztreonam	R	-	-	-	-	-	-	-	-	-	-	-	-	-	83	45	R	-	
Ertapenem	R	99	91	0	100	100	96	100	100	100	100	100	-	98	R	R	R	-	
Meropenem	-	-	-	-	-	-	-	-	-	-	-	-	100 ^b	-	95	0	R	100 ^b	
Ciprofloxacin	90	96	96	84	85	26	97	99	93	20	80	18	83	93	87	58	-	-	
Levofloxacin	96	95	94	77	81	16	94	98	91	12	80	25	-	94	82	45	91	-	
Gentamicin	96	99	99	100	93	76	100	100	97	56	90	37	R	99	R	R	R	-	
Tobramycin	100	99	99	95	93	69	100	99	97	53	91	18	R	86	98	88	R	-	
Trimethoprim/ Sulfamethoxazole	93	96	94	91	81	47	99	97	94	24	85	12	92	99	R	R	88	-	
Nitrofurantoin ^c	-	88	42	51	98	90	13	85	28	13	R	R	-	R	R	R	-	-	

a) Results from 2023 and 2024; invasive isolates only

b) < 30 isolates or subset of total isolates; results may not be statistically significant

c) urine only

-) not tested, not reported, or insufficient data

*) reported as resistant for ESBL; treatment not recommended

R) intrinsically resistant or clinically ineffective; treatment not recommended

% susceptible ≥ 90

% susceptible 60-89

% susceptible < 60 or R

Alternative color palette